Recombinant MSH2 antibody (full length)

Catalog No. ABIN7878623

This Mouse Monoclonal antibody specifically detects MSH2 in WB and IHC (p). It exhibits reactivity toward Human, Dog and Cat.

Quick Overview for Recombinant MSH2 antibody (full length) (ABIN7878623)

Target: MSH2 (Mismatch Repair Protein 2 (MSH2))

Antibody Type: Recombinant Antibody

Reactivity: Human, Dog, Cat

Host: Mouse

Clonality: Monoclonal

Conjugate: This MSH2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: RMSH2-6548

Product Details anti-MSH2 Antibody

Binding Specificity: full length

Purpose: Recombinant MSH2 Antibody (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human MSH2 protein was used as the immunogen for the recombinant MSH2 antibody.

Isotype: IgG2a, kappa

Application Details

Application Notes: Optimal dilution of the recombinant MSH2 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the recombinant MSH2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for MSH2

Target: MSH2 (Mismatch Repair Protein 2 (MSH2))

Alternative Name: MSH2

Background: Mutations in DNA mismatch repair genes are associated with hereditary nonpolyposis colorectal cancer (HNPCC). Initially, inherited mutations in the MSH2 and MLH1 homologs of the bacterial DNA mismatch repair genes MutS and MutL were found at high frequency in HNPCC and were shown to be associated with microsatellite instability. The demonstration that 10 to 45 % of pancreatic, gastric, breast, ovarian and small cell lung cancers also display microsatellite instability has been interpreted to suggest that DNA mismatch repair is not restricted to HNPCC tumors but is a common feature in tumor initiation or progression.

Pathways: DNA Damage Repair, Production of Molecular Mediator of Immune Response